Monensin |
Catalog No.GC61079
One-Click Copy Product Info
|
Monensin is a polyether ionophore antibiotic with anticancer activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 17090-79-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Monensin is a polyether ionophore antibiotic with anticancer activity. Monensin selectively binds monovalent cations such as Na⁺ and K⁺ and mediates Na⁺/H⁺ exchange. Monensin inhibits Gram-positive bacteria and coccidia by disrupting intracellular ion gradients, osmotic pressure and pH homeostasis. Monensin interferes with Golgi protein transport and inhibits autophagic flux. Monensin can be used in research related to bacterial infections, coccidiosis, viral infections, and cancer[1-4].
In vitro, Panc-1 and MiaPaCa-2 cells were treated with 0.5-8µM Monensin for 48-72 hours. Monensin inhibited cell proliferation and migration, arrested the cell cycle at the sub-G1 phase and decreased the S-phase population, and increased the proportion of apoptotic cells[5]. UOK146 cells were treated with 5-25µM Monensin for 24 hours. Monensin induced cell death, caused vacuolar morphological changes, and decreased mitochondrial membrane potential[6]. H1299 cells were treated with 500nM Monensin for 0-24 hours. Monensin reduced GOLIM4 protein levels in the Golgi apparatus and inhibited cell migration and invasion[7].
In vivo, BALB/c mice were intranasally sensitized with 10μg house dust Mite extract (HDM) twice weekly for 6 weeks. Monensin was administered via i.p. (1mg/kg) or i.n. (0.25-1mg/kg) 30min prior to each sensitization. Monensin reduced total cell, eosinophil and lymphocyte counts in bronchoalveolar lavage fluid, decreased lung inflammation scores, and alleviated lung tissue inflammation[8]. 4T1-Luc2 tumor xenograft BALB/c mice were intraperitoneally injected with 8mg/kg Monensin daily for 10 consecutive days. Monensin increased intracellular Na⁺ levels in tumor cells, reduced tumor volume, and induced extensive tumor necrosis[9]. Apc+/Min mice were orally gavaged with 10mg/kg Monensin daily for 6 consecutive weeks. Monensin reduced average intestinal tumor area and total tumor area per animal, increased the number of apoptotic cells and p21-positive cells on the tumor surface, and did not change tumor number[10].
References:
[1] Potter EL, VanDuyn RL, Cooley CO. Monensin toxicity in cattle. J Anim Sci. 1984 Jun;58(6):1499-511.
[2] Zeng C, Long M, Lu Y. Monensin synergizes with chemotherapy in uveal melanoma through suppressing RhoA. Immunopharmacol Immunotoxicol. 2023 Feb;45(1):35-42.
[3] Li Y, Sun Q, Chen S, et al. Monensin Inhibits Anaplastic Thyroid Cancer via Disrupting Mitochondrial Respiration and AMPK/mTOR Signaling. Anticancer Agents Med Chem. 2022;22(14):2539-2547.
[4] Donoho AL. Biochemical studies on the fate of monensin in animals and in the environment. J Anim Sci. 1984 Jun;58(6):1528-39.
[5] Wang X, Wu X, Zhang Z, et al. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Scientific Reports. 2018 Dec 17;8:17914.
[6] Verma SP, Das P. Monensin induces cell death by autophagy and inhibits matrix metalloproteinase 7 (MMP7) in UOK146 renal cell carcinoma cell line. In Vitro Cellular & Developmental Biology - Animal. 2018 Oct;54(8):736-42.
[7] Tan X, Cardin DL, Wang S, et al. Monensin suppresses EMT-driven cancer cell motility by inducing Golgi pH-dependent exocytosis of GOLIM4. PNAS. 2025 Jul 9;122(28):e2501347122.
[8] Allam VSRR, Akula S, Waern I, et al. Monensin suppresses multiple features of house dust mite-induced experimental asthma in mice. Inflammation. 2025;48:806-19.
[9] Fiorilla S, Tasso F, Clemente N, et al. Monensin inhibits triple-negative breast cancer in mice by a Na+-dependent cytotoxic action unrelated to cytostatic effects. Cells. 2025 Jan 25;14(3):185.
[10] Tumova L, Pombinho AR, Vojtechova M, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Molecular Cancer Therapeutics. 2014 Apr;13(4):812-22.
| Cell experiment [1]: | |
|
Cell lines |
Panc-1 cells (human pancreatic ductal adenocarcinoma cell line), MiaPaCa-2 cells (human pancreatic ductal adenocarcinoma cell line) |
|
Preparation Method |
Panc-1 and MiaPaCa-2 cells were maintained in DMEM with 10% FBS at 37°C, 5% CO2. Cells were treated with 0.5-4µM Monensin for 48-72h. After treatment, WST-1 assay, crystal violet staining, wound-healing assay, Transwell migration assay (4µM, 12h), cell cycle analysis (2µM, 48h, Hoechst 33258/flow), Annexin V-FITC/PI apoptosis assay (48h), Gaussia luciferase reporter assay for E2F/DP1/STAT1/2/NFκB/AP-1/Elk-1/SRF (24-48h), TqPCR for EGFR/RAF1/KRAS/NRAS/MEK1 (48h), and immunofluorescence for EGFR (36h) were performed. |
|
Reaction Conditions |
0.5-4µM; 48-72h |
|
Applications |
Monensin suppressed cell proliferation and colony formation, reduced wound closure and Transwell migration cell numbers, increased sub-G1 population and decreased S-phase population, increased early and late apoptotic cell percentages, inhibited E2F/DP1, STAT1/2, NFκB, AP-1 and Elk-1/SRF reporter activities, downregulated EGFR and RAF1 mRNA, reduced membrane EGFR immunofluorescence, and upregulated KRAS, NRAS and MEK1 mRNA in Panc-1 and MiaPaCa-2 cells. |
| Animal experiment [2]: | |
|
Animal models |
6-8-week-old female BALB/c mice |
|
Preparation Method |
Mice were orthotopically injected with 100000 4T1-Luc2 triple-negative breast cancer cells into the fourth mammary fat pad. When tumor volume reached ~80mm3, mice received daily intraperitoneal injection of 8mg/kg Monensin (dissolved in DMSO/2-hydroxypropyl-β-cyclodextrin 10% in 0.9% NaCl, 1:9 v/v) for 10 days. In vivo IVIS Spectrum imaging (CoroNa Green-AM for intratumoral Na⁺, D-luciferin for tumor mass), caliper tumor measurement, H&E histology, Ki-67 IHC of tumor/intestine/bone marrow/lung/liver/spleen/kidney/brain/heart, and QuPath morphometry (cell density, equivalent circular diameter) were performed 2h after last dose. |
|
Dosage form |
8mg/kg; i.p.; daily for 10 days |
|
Applications |
Monensin reduced tumor volume (0.146±0.06cm³ vs 0.468±0.2cm³), reduced luciferin signal, increased CoroNa Green-AM fluorescence in tumor (not in healthy tissues), induced extensive tumor necrosis, increased tumor cell equivalent circular diameter, reduced tumor cell density, and did not alter Ki-67 positivity in tumor or intestine/bone marrow, nor cause morphological damage in lung/liver/spleen/kidney/brain/heart or change body weight/survival. |
References: [1] Wang X, Wu X, Zhang Z, et al. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Scientific Reports. 2018 Dec 17;8:17914. [2] Fiorilla S, Tasso F, Clemente N, et al. Monensin inhibits triple-negative breast cancer in mice by a Na+-dependent cytotoxic action unrelated to cytostatic effects. Cells. 2025 Jan 25;14(3):185. | |
| Cas No. | 17090-79-8 | SDF | |
| Canonical SMILES | C[C@]1([C@]2([H])O[C@@](CC2)([C@]3([H])O[C@]([C@@]4([H])O[C@](O)([C@@H](C[C@@H]4C)C)CO)([H])C[C@@H]3C)CC)O[C@@]5(CC1)O[C@]([C@@H]([C@H](C5)O)C)([H])[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O | ||
| Formula | C36H62O11 | M.Wt | 670.87 |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4906 mL | 7.453 mL | 14.906 mL |
| 5 mM | 298.1 μL | 1.4906 mL | 2.9812 mL |
| 10 mM | 149.1 μL | 745.3 μL | 1.4906 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)